Ovarian Cancer

CRX100 plus a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in patients with recurrent, platinum-resistant ovarian cancer.

From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

Mirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer.

Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

First-line niraparib maintenance was not associated with worsened health-related quality of life outcomes vs placebo in advanced ovarian cancer.

PARP inhibitors have shown promise in ovarian cancer treatment, but certain subgroups of patients have few effective options following disease progression.

Avutometinib alone or in combination with defactinib has received an orphan drug from the FDA for recurrent low-grade serous ovarian cancer.

HIPEC was not associated with additional complications or worse survival in patients with FIGO stage IV ovarian cancer vs those with stage III disease.

Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer—its hunger for cholesterol.

Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.

Hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery improved progression-free survival in stage III epithelial ovarian cancer.

FDA grants fast-track status to BNT325/DB-1305 for patients with platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.

Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.

Eirwen M. Miller, MD, discusses updates on antibody-drug conjugates and emerging targets in ovarian cancer.

Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.

Eirwen M. Miller, MD, discusses how mirvetuximab soravtansine-gynx in ovarian cancer has bolstered the development of novel ADCs in ovarian cancer.

The FDA has granted fast-track status to RC88 for use in patients with platinum-resistant recurrent epithelial ovarian cancer.

Sarah Crafton, MD, discusses novel therapeutic targets under investigation in patients with ovarian cancer.

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

The FDA has granted fast track designation to rinatabart sesutecan for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.